• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Puma Biotechnology Inc

    8/27/24 5:02:49 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBYI alert in real time by email
    S-8 1 pbyi20240826_s8.htm FORM S-8 pbyi20240826_s8.htm

    As filed with the Securities and Exchange Commission on August 27, 2024

     

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

    PUMA BIOTECHNOLOGY, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    77-0683487

    (State or other jurisdiction of

    incorporation or organization)

    (IRS Employer

    Identification No.)

     

    10880 Wilshire Boulevard, Suite 2150

    Los Angeles, California 90024

    (Address of principal executive offices) (Zip code)

     

    Puma Biotechnology, Inc. 2011 Incentive Award Plan

    (Full title of the plan)

     

    Alan H. Auerbach

    President and Chief Executive Officer

    Puma Biotechnology, Inc.

    10880 Wilshire Boulevard, Suite 2150

    Los Angeles, California 90024

    (424) 248-6500

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    B. Shayne Kennedy, Esq.
    Drew Capurro, Esq.

    Latham & Watkins LLP

    650 Town Center Drive, 20th Floor

    Costa Mesa, California 92626

    (714) 540-1235

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

                 

    Large accelerated filer

     

    ☐

     

    Accelerated filer

     

    ☒

           

    Non-accelerated filer

     

    ☐ 

     

    Smaller reporting company

     

    ☒

           
           

    Emerging growth company

     

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    INTRODUCTION

     

    On June 18, 2024, the stockholders of Puma Biotechnology, Inc. (the “Company” or the “Registrant”) approved an amendment to the Puma Biotechnology, Inc. 2011 Incentive Award Plan (the “2011 Plan”), increasing the number of authorized shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), that may become issuable under the 2011 Plan by 3,000,000 shares and extending the period during which incentive stock options may be granted. The Company is filing this registration statement (this “Registration Statement”) on Form S-8 to register such additional shares.

     

    The Company has previously registered 3,529,412 shares of Common Stock issuable under the 2011 Plan on the registration statement on Form S-8 (Reg. No. 333-181703) filed with the Securities and Exchange Commission (the “Commission” or the “SEC”) on May 25, 2012, 3,000,000 shares of Common Stock issuable under the 2011 Plan on the registration statement on Form S-8 (Reg. No. 333-196993) filed with the Commission on June 24, 2014, 4,000,000 shares of Common Stock issuable under the 2011 Plan on the registration statement on Form S-8 (Reg. No. 333-205117) filed with the Commission on June 19, 2015, 2,000,000 shares of Common Stock issuable under the 2011 Plan on the registration statement on Form S-8 (Reg. No. 333-219347) filed with the Commission on July 19, 2017 and 2,000,000 shares of Common Stock issuable under the 2011 Plan on the registration statement on Form S-8 (Reg. No. 333-259585) filed with the Commission on September 16, 2021 (the “Prior Registration Statements”). Under this Registration Statement, the Company is registering an additional 3,000,000 shares of Common Stock issuable under the 2011 Plan. Pursuant to General Instruction E of Form S-8 regarding Registration of Additional Securities, the contents of the Prior Registration Statements are incorporated by reference herein to the extent not modified or superseded hereby or by any subsequently filed document that is incorporated by reference herein or therein.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Commission. The Registrant will deliver the documents containing the information specified in Part I of Form S-8 to the 2011 Plan participants as specified by the Commission Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 6. Indemnification of Directors and Officers

     

    Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware (the “DGCL”), empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person’s conduct was unlawful.

     

     

     

     

    Subsection (b) of Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    Section 145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person’s heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.

     

    Section 102(b)(7) of the DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.

     

    Any underwriting agreement or distribution agreement that the Registrant enters into with any underwriters or agents involved in an offering or sale of any securities registered by the Registrant may require such underwriters or dealers to indemnify the Registrant, some or all of its directors and officers and its controlling persons, if any, for specified liabilities, which may include liabilities under the Securities Act of 1933, as amended.

     

    Our amended and restated bylaws provide that we will indemnify and hold harmless, to the fullest extent permitted by applicable law, any person (all such persons being referred to as a “Covered Person”) who was or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding (other than a Proceeding commenced by such Covered Person unless such commencement was authorized by our Board of Directors), whether civil, criminal, administrative or investigative (referred to as a “Proceeding”), by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was our director or officer or, while our director or officer, is or was serving at our request as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys’ fees) reasonably incurred by such Covered Person. We will also, to the fullest extent not prohibited by applicable law, pay the expenses (including attorneys’ fees) incurred by a Covered Person in defending any Proceeding in advance of its final disposition, provided, however, that, to the extent required by law, such payment of expenses in advance of the final disposition of the Proceeding will be made only upon receipt of an undertaking by the Covered Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified by us.

     

    We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including reasonable attorneys’ fees, judgments, fines, penalties and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any other company or enterprise to which the person provides services at our request.

     

     

     

     

    We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

     

    Item 8. Exhibits.

     

    Exhibit
    Number

     

    Description

       

    4.1

     

    Second Amended and Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 14, 2016 (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 15, 2016 and incorporated herein by reference)

       

    4.2

     

    Fourth Amended and Restated Bylaws of the Company (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on August 18, 2023 and incorporated herein by reference)

       

    4.3

     

    Form of Common Stock Certificate (filed as Exhibit 4.1 to the Company’s Registration Statement on Form S-1/A filed with the SEC on February 1, 2012 and incorporated herein by reference)

       

    5.1+

     

    Opinion of Latham & Watkins LLP

       

    23.1+

     

    Consent of KPMG LLP

       

    23.2+

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1)

       

    24.1+

     

    Power of Attorney (included on signature page)

       

    99.1

     

    Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on October 11, 2011 and incorporated herein by reference)

       

    99.2

     

    First Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Appendix A to the Company’s Proxy Statement on Form DEFR14A filed with the SEC on June 4, 2014 and incorporated herein by reference)

       

    99.3

     

    Second Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 10, 2015 and incorporated herein by reference)

       

    99.4

     

    Third Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 14, 2017 and incorporated herein by reference)

       

    99.5

     

    Fourth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on June 14, 2017 and incorporated herein by reference)

       

    99.6

     

    Fifth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 17, 2021 and incorporated herein by reference)

       

    99.7

     

    Sixth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 24, 2024 and incorporated herein by reference)

       

    99.8

     

    Form of Stock Option Grant Notice and Stock Option Agreement, issued pursuant to the 2011 Incentive Award Plan (filed as Exhibit 10.5 to the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2012 and incorporated herein by reference)

       

    99.9

     

    Form of Chief Executive Officer Stock Option Grant Notice and Stock Option Agreement, issued pursuant to the 2011 Incentive Award Plan (filed as Exhibit 10.6 to the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2012 and incorporated herein by reference)

       

    99.10

     

    Form of Restricted Stock Unit Award Agreement, issued pursuant to the 2011 Incentive Award Plan (filed as Exhibit 99.9 to the Company’s Registration Statement on Form S-8 filed with the SEC on September 16, 2021 and incorporated herein by reference)

         

    107+

     

    Filing Fee Table

       

    +

    Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on August 27, 2024.

     

         

    PUMA BIOTECHNOLOGY, INC.

       

    By:

     

    /s/ Alan H. Auerbach

       

    Alan H. Auerbach

       

    President and Chief Executive Officer

     

     

    SIGNATURES AND POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Alan H. Auerbach and Maximo F. Nougues, and each of them, his true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement on Form S-8, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

             

    Signature

     

    Title

     

    Date

         

    /s/ Alan H. Auerbach

     

    Chairman of the Board of Directors,

     

    August 27, 2024

    Alan H. Auerbach   President and Chief Executive Officer (Principal Executive Officer)    
         

    /s/ Maximo F. Nougues

     

    Chief Financial Officer

     

    August 27, 2024

    Maximo F. Nougues   (Principal Financial and Accounting Officer)    
         

    /s/ Alessandra Cesano

     

    Director

     

    August 27, 2024

    Alessandra Cesano        
         

    /s/ Allison Dorval

     

    Director

     

    August 27, 2024

    Allison Dorval        
         

    /s/ Michael P. Miller

     

    Director

     

    August 27, 2024

    Michael P. Miller        
         

    /s/ Jay M. Moyes

     

    Director

     

    August 27, 2024

    Jay M. Moyes        
         

    /s/ Adrian M. Senderowicz

     

    Director

     

    August 27, 2024

    Adrian M. Senderowicz        
         

    /s/ Brian Stuglik

     

    Director

     

    August 27, 2024

    Brian Stuglik        
         

    /s/ Troy E. Wilson

     

    Director

     

    August 27, 2024

    Troy E. Wilson        

     

     
    Get the next $PBYI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBYI

    DatePrice TargetRatingAnalyst
    9/28/2021$11.00Neutral → Buy
    Citigroup
    9/28/2021Neutral → Buy
    Citigroup
    8/6/2021$13.00 → $6.00Sector Perform
    RBC Capital
    8/6/2021$9.00 → $8.00Sell
    Goldman Sachs
    More analyst ratings

    $PBYI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Auerbach Alan H sold $204,878 worth of shares (34,950 units at $5.86), decreasing direct ownership by 0.49% to 7,145,951 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    1/8/26 8:27:45 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Hunt Douglas M sold $52,696 worth of shares (8,987 units at $5.86), decreasing direct ownership by 5% to 155,907 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    1/8/26 8:15:27 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Nougues Maximo F sold $64,187 worth of shares (10,945 units at $5.86), decreasing direct ownership by 5% to 193,284 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    1/8/26 8:14:50 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBYI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, February 1

    2/4/26 5:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 6, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 10,500 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, January 1

    1/7/26 5:15:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ:NBI), effective at the close of trading on Friday, December 19, 2025. "Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma's continued commercial execution, profitability, and clinical progress," said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. "With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients and shareholders."

    12/22/25 4:10:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBYI
    SEC Filings

    View All

    SEC Form 144 filed by Puma Biotechnology Inc

    144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    1/7/26 4:28:49 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Puma Biotechnology Inc

    144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    1/6/26 4:45:54 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Puma Biotechnology Inc

    144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    1/6/26 4:44:04 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBYI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Puma Biotech. upgraded by Citigroup with a new price target

    Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00

    9/28/21 7:42:41 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology upgraded by Citigroup

    Citigroup upgraded Puma Biotechnology from Neutral to Buy

    9/28/21 4:54:51 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital reiterated coverage on Puma Biotechnology with a new price target

    RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously

    8/6/21 10:44:06 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBYI
    Financials

    Live finance-specific insights

    View All

    Puma Biotechnology Reports Third Quarter 2025 Financial Results

    Raising 2025 NERLYNX® revenue and net income estimates Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless otherwise stated, all comparisons are for the third quarter of 2025 compared to the third quarter of 2024. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2025 was $51.9 million, compared to $56.1 million in the third quarter of 2024. Product revenue, net in the first nine months of 2025 was $144.2 million, compared to $140.8 million in the first nine months of 2024. Based on accountin

    11/6/25 4:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, Nov. 6, 2025, following the release of its third quarter 2025 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay will be available shortly after completion of the call a

    10/23/25 4:10:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Puma Biotechnology Reports Second Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2025. Unless otherwise stated, all comparisons are for the second quarter 2025 compared to the second quarter 2024. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2025 was $49.2 million, compared to product revenue, net of $44.4 million in the second quarter of 2024. Product revenue, net in the first six months of 2025 was $92.3 million, compared to $84.6 million in the first six months of 2024. Based on accounting principles generally accepted in th

    8/7/25 4:05:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBYI
    Leadership Updates

    Live Leadership Updates

    View All

    Puma Biotechnology to Join Russell 3000 Index

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

    5/28/24 9:00:00 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

    Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

    11/17/22 4:15:00 PM ET
    $EPIX
    $PBYI
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

    Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

    8/15/22 5:00:00 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBYI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Puma Biotechnology Inc

    SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    3/29/24 10:40:57 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

    SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    2/14/24 8:19:11 AM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)

    SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)

    2/13/24 5:12:15 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care